NuSep Holdings Ltd 30 Richmond Rd

Homebush NSW 2140

Postal Address P.O. Box 2202

Homebush West NSW 2140

Contact Details

Telephone +61 2 8415 7300

Facsimile +61 2 8415 7399

Email info@nusep.com

Web www.nusep.com

ABN 33 120 047 556

FOR IMMEDIATE RELEASE

NuSep Investor Presentation

Sydney, Australia 10th July 2013– NuSep (ASX:NSP). Attached is the latest investor presentation by the Company. **ENDS** For more information please contact: Contact: Prakash Patel Managing Director +61 2 8415 7300 About NuSep NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA. With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME1 technology. The PrIME technology has produced a number of world firsts including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification. NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia. NuSep Products:

Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

1 PrIME stands for Preparative Isolation by Membrane Electrophoresis

For

per

sona

l use

onl

y

– 2 –

For more information about NuSep please visit the company’s website www.NuSep.com About PrIME Biologics Pte Ltd PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. NuSep has a 90% shareholding in PrIME Biologics. PrIME Biologics process is based on the Preparative Isolation by Membrane Electrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation. The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers. The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.

For

per

sona

l use

onl

y

NuSep InvestorPresentation

July 2013

For

per

sona

l use

onl

y

DISCLAIMER

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

For

per

sona

l use

onl

y

The PrIME Opportunity

The Problem

•Acute Shortage of Asian Emergency Plasma Drugs; and

•The Raw Material (plasma) is currently Discarded.

The Solution

PrIME opens $2b Asian market by processing waste plasma using unique PrIME Technology

Investment Return

•Create multi billion Company;

•Investment of $15m;

•NPV $84m @20% discount & IRR of 38%.

PrIME stands for Preparative Isolation by Membrane Electrophoresis

For

per

sona

l use

onl

y

PrIME Business Model

$2BMay 2013

Acute Shortage of AsianEmergency Plasma Drugs

SingaporecGMP

Manufacturing Facility

Fractionation(PrIME)

TechnologyWas

tePl

asm

a

Clin

ical

Tr

ial

24 Months

Waste Plasma

Over 50% of all Plasma Collected in Asia is thrown away.

Singapore Facility

•cGMP facility;•Pilot PrIME installed;•3 batches of cGMP Albumin.

PrIME Technology

•Unique technology;•Opens up the untapped Asian Market.

Clinical Trial

•40 Patient, 12 months trial;•10 patients already identified.

$2B

For

per

sona

l use

onl

y

5 Steps to First Sales

cGMPApproval

Recommission Facility

Lodge application

Audit by HSAApproval post

audit

Manufacture Clinical Products

Make 3 batches of each product

Put product aside for stability testing

Start Clinical Trial

CRO will run the clinical trials

Follow patients for 12 months

Collect and analyse data

Apply for Registration

Submit data to HSA for registration

Product Registration

First sales will occur on Product Registration by HSA

Registration & First Sales in $2B Market

cGMP Facility Approval

Manufacture Clinical Product

Start Clinical Trials

Finish Trials/Apply for Registration

Dec 2013 March 2014 April 2014 April 2015 Dec 2015

CUPJUNE 2014

For

per

sona

l use

onl

y

5 Steps Process

cGMPApproval

Manufacture Clinical Products

Start Clinical Trial

Apply for Registration

Product Registration

Start up EquipmentWrite up processesLodge applicationUndertake audit

Make 3 production batchesQC batchesShip to Clinical trail sitesStart stability testing

Truncated clinical trail40 patients over 12 monthsEndpoint, same as existing products

Write up trial resultsSubmit to HSARespond to HSA questionsReceive HSA approval

PrIME Value(at each of the 5 Steps)

cGMP Approval

Manufacture Clinical Product

Start Clinical Trial

Apply for Registration

2015 P/E Market ValueRisk Weighting

(value as % of 2015 Market Value)25% 40% 70% 90%

Base Case $110m $190m $330m $420m $460m

Contract Case $230m $370m $650m $840m $930m

Optimistic Case $310m $500m $880m $1,130m $1,250mFor

per

sona

l use

onl

y

AsianPlasma Disposable

Process

• Processing the ‘Waste’ or Currently Unprocessable Plasma (CUP) allows self sufficiency for regional areas.

Low Cost Therapeutic Products

• To Process CUP requires a disposable production method - NuSep’s patented PrIME process is such a process.

Market Entry Strategy – CUP Market 

For

per

sona

l use

onl

y

Market Entry Model and Order book

Order Book – Yearly

Singapore:  10,000 LitresIndia:  50,000 Litres

Revenue:  S$32M (A$25M)

Plasma is drawn from India, Processed in Singapore and sold back to India as an Active Ingredient

Model

For

per

sona

l use

onl

y

PrIME Biologics Budget

Budget in S$Calendar years

2013S$M

2014S$M

2015S$M

2016S$M

PrIME% to Sales

Cohn % to Sales

PrIME∆to Cohn

Sales $- $- $33.5 $62

Gross Profit ($0.6) $0.4 $26.5 $50.5 81% ~50% +62%

EBITDA ($4.2) ($4.7) $22.9 $46.3 74% ~40% +85%

NPAT ($4.3) ($5.2) $20.2 $37.9 60% ~35% +71%

NPV on the PrIME Biologics Project using a 20% Discount is S$84mIRR on the PrIME Biologics Project is 38%

For

per

sona

l use

onl

y

PrIME GF100 in situ at PrIME’s Singapore Fractionation Facility

For

per

sona

l use

onl

y

PrIME Sustainable Competitive Advantage

The PrIME1 Technology addresses the acute shortage of emergency plasma drugs in Asia by processing the wasted

plasma and producing a safer, cheaper locally manufactured product. PrIME achieves this by:

•Processing the Wasted PlasmaPlasma represents 45% of the cost of the current therapeutic products;

•High Product Yield, Small batch size & Short production runs PrIME produces twice the end product in less time and smaller batches from a Litre of plasma than the current processes;

•Added Product SafetyPrIME removes viruses and Prions other systems can’t;

•Low Capital CostPrIME is a low capital cost process.

1 PrIME is Preparative Isolation by Membrane Electrophoresis

For

per

sona

l use

onl

y

The PrIME Technology

PrIME is a platform technology and NuSep is developing the following applications:

•Current ApplicationTherapeutic Plasma Fractionation - ($10b);

•Applications Under DevelopmentSperm Separation – (100m);Dengue Diagnostic & Therapy – ($1b)

•Future Applications could includeDialysis – ($19b);Recombinant Separations – ($60b);Toxin Removal.

Each new application creates a new annuity sales stream for NuSep.

For

per

sona

l use

onl

y

PrIME Technology Applications

PrIME Fractionation $10B

60B

Sub 1B

Time to Market

Market Size

IVF $100m Market

20B

10B

2014 2015 2016 2017 2018

Renal Dialysis $19B

Recombinant Therapeutics $60B

For

per

sona

l use

onl

y

3 Step Business Model

1. Develop applications of the PrIME Technology to better address existing markets

2. Spin out new applications as separate companies bring in new investors to fund and give NuSep shareholders in species distribution

3. Each application generates a new annuity sales stream for NuSep

For

per

sona

l use

onl

y

Clinical IVF Products Time LineF

or p

erso

nal u

se o

nly

PrIME Achievements

• Grant from Singapore Government.

• ABS agreement to fractionate CUP.

• Acquisition of Singapore cGMP facility.

• Transfer of Pilot Scale PrIME unit to Singapore.

• Appointment of key regulatory personnel.

• Decision to Spin Out PrIME.

• Future PrIME funding pending.

For

per

sona

l use

onl

y

Dollar Value Comparison of Existing Cohn Process vs PrIME

Plasma Product

Plasma Con1

g/L

Value per g protein

Cohn2

Yield g/L

Cohn % Yield

Cohn $/L PrIME3Yield g/L

PrIME % Yield

PrIME $/L Δ g/L Cohn to PrIME4

100,000L pa Δ Cohn & PrIMEKg                          $M5

Albumin 40g $2.50 25g 65% $62.5 34g 85% $85.0 9g/L 0.9kg $2.25m

IVIG 10g $50.00 4g 40% $200 8g 80% $400 4g/L 0.4kg $20m

Total $52.50 29g $262.50 42g $485.00 13g/L 1.3kg $22.25m

KEY1.This is the normal concentration of these proteins in a litre of Human Plasma.2.Cohn fractionation is the technology used by the existing fractionators.3.PrIME is the disposable manufacturing process used by PrIME Biologics.4.This column shows the additional protein per gram manufactured using the PrIME process.5.This column shows the additional profit gained by using the PrIME over the Cohn process.F

or p

erso

nal u

se o

nly

For more information see:www.NuSep.comPhone +61 2 8415 7300

For

per

sona

l use

onl

y